Therefore, it is important to assess whether T‐cell regulatory molecules can be used as biomarkers to predict tumor resistance and guide the choice of therapy, which is why we investigated the preoperative serum levels of B7 family molecules and CD28 family receptors in RCC patients as well as their associations with clinicopatological features. This evidence concerns the gene CD28 and renal cell carcinoma.